CoChat

Fatal Aspiration Pneumonia as a Complication of Fecal Microbiota Transplant

Open access
Baxter, M., Ahmad, T., Colville, A., Sheridan, R. · 2015 · Clinical Infectious Diseases
Cited by 126

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

To the Editor—Fecal microbiota transplant (FMT) is increasingly being used to treat refractory Clostridium difficile infection (CDI). The growing body of evidence indicates that the procedure is efficacious, with low rates of reported adverse events [1, 2]. Of 14 patients treated with FMT at our center, we report the first complication, highlighting the consequent changes to our practice. An 80-year-old patient with a past medical history of vasculopathy, osteoarthritis, and gout presented with recurrent CDI. The infection proved refractory to 3 courses of vancomycin, 2 of metronidazole, 1 of fidaxomicin, and 1 additional vancomycin course. Pseudomembranous colitis was confirmed on flexible sigmoidoscopy. In December 2013 radiologically guided insertion of a nasojejunal tube failed due to technical difficulties experienced when accessing the duodenum. An attempt to endoscopically place a nasojejunal tube was abandoned owing to epistaxis. In February 2014, the FMT was delivered to the distal duodenum via the biopsy channel of an enteroscope, on this occasion under general anesthesia. Using a 50-mL syringe, 100–150 mL of solution was instilled over 12 minutes. Feculent liquid was regurgitated during the third 50-mL aliquot and the procedure was terminated immediately. Initially physiologically stable, the patient's condition deteriorated in the subsequent hours, with pyrexia of 38.3°C, increasing oxygen requirements, and further vomiting. Renal function deteriorated from baseline urea of 9.9 mmol/L to 14.7 mmol/L and creatinine from baseline 102 µmol/L to 135 µmol/L. C reactive protein rose to 164 mg/L from 4 mg/L pre-procedure and white cell count fell to 3.5 × 109/L from 10 × 109/L. Chest X-ray showed left midzone airspace shadowing. Intravenous metronidazole was commenced and oral vancomycin continued. Computed tomography pulmonary angiogram (CTPA) excluded pulmonary embolus and confirmed widespread bilateral consolidation. During the next 48 hours the patient's condition worsened. Metronidazole was substituted by meropenem. Septic shock supervened, necessitating intensive care unit (ICU) admission for multiorgan support. Sputum culture isolated Escherichia coli and Pseudomonas aeruginosa. Blood cultures also isolated E. coli. Linezolid and fluconazole were added empirically. Once discharged to a medical ward 14 days later, a turbulent course ensued, with several episodes of sepsis necessitating 2 additional admissions to the ICU. Repeat blood cultures proved sterile throughout. CTPA was again negative for pulmonary embolus and confirmed persistent dense consolidation of the left lower lobe. Despite treatment at this time with meropenem and caspofungin, the patient died of pneumonia 48 days post FMT procedure. Stool samples tested negative for C. difficile glutamate dehydrogenase and toxin A/B (Techlab Quik Check Complete, Orlando, Florida) on days 4, 11, 13, and 42 post FMT. To our knowledge, this is the third reported death attributable to FMT; the others were due to toxic megacolon and septic shock [3] and to aspiration during sedation for colonoscopic FMT [4]. Our protocol now includes administration of an anti-emetic pre-procedure. General anesthetic is not common practice in FMT; therefore, the risk of aspiration peri-procedure may not be generalizable. We suggest that FMT via the upper gastrointestinal tract be performed only in the awake patient, with consideration of colonoscopic FMT when general anesthesia is required. Potential conflicts of interest. All authors: No potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/civ247

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 126

Metadata

Authors
Baxter, M., Ahmad, T., Colville, A., & Sheridan, R.
Venue
Clinical Infectious Diseases
Published
2015-03-24
Volume
61
Issue
1
Pages
136-137
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2068375039
Cited by
126
References
2
FWCI
9.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.